2.2674

1.52% -0.0326

Larimar Therapeutics Inc (LRMR)

Overview News Price History Option Chain Financials Discussions Forecast

Larimar Therapeutics Inc stock is traded at $2.2674, with a volume of 977.83K. It is down -1.52% in the last 24 hours and down -14.53% over the past month. Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Previous Close:

$2.30

Open:

$2.3

24h Volume:

977.83K

Relative Volume:

0.91

Market Cap:

$145.03M

Revenue:

Net Income/Loss:

$-36.95M

P/E Ratio:

-2.6993

EPS:

-0.84

Net Cash Flow:

$-33.46M

1W Performance:

+21.12%

1M Performance:

-14.53%

6M Performance:

-64.22%

1Y Performance:

-68.10%

1-Day Range:

$2.13

$2.32

1-Week Range:

$1.80

$2.33

52-Week Range:

$1.61

$11.20

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name

Larimar Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

844-511-9056

Address

THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA

Employee

Twitter

Next Earnings Date

2025-03-24

Latest SEC Filings

LRMR's Discussions on Twitter

Compare LRMR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LRMR Larimar Therapeutics Inc	2.265	123.57M	0	-36.95M	-33.46M	-0.84
ONC Beone Medicines Ltd Adr	245.47	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.48	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.33	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.24	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.24	64.44B	14.09B	4.50B	2.96B	39.28

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-25	Initiated	Truist	Buy
Oct-16-24	Initiated	Oppenheimer	Outperform
Oct-03-24	Initiated	Wedbush	Outperform
Oct-02-24	Initiated	H.C. Wainwright	Buy
Sep-04-24	Initiated	Robert W. Baird	Outperform
Apr-03-24	Initiated	Leerink Partners	Outperform
Nov-17-23	Upgrade	Citigroup	Neutral → Buy
Oct-19-22	Initiated	Guggenheim	Buy
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform

View All

Larimar Therapeutics Inc Stock (LRMR) Latest News

May 23, 2025

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN

May 23, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa

May 23, 2025

May 22, 2025

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com

May 22, 2025

May 18, 2025

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo

May 18, 2025

May 13, 2025

Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

May 13, 2025

May 06, 2025

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN

May 06, 2025

May 04, 2025

Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks

May 04, 2025

May 02, 2025

Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel

May 02, 2025

The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News

May 02, 2025

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail

May 02, 2025

Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World

May 02, 2025

May 01, 2025

LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com

May 01, 2025